# A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

> **NCT01087203** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 73 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathy

## Interventions

- **BIOLOGICAL:** Tanezumab
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT01087203
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03-30
- **Primary completion:** 2010-11-18
- **Final completion:** 2011-07-06
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01087203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01087203, "A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01087203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*